Skye Bioscience, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye Bioscience" or the "Company") (SKYE). Impacted investors are advised to contact the firm now.

Attorneys are investigating whether Skye Bioscience misrepresented or omitted material information regarding the development and prospects of its lead asset, nimacimab. From approximately August 2024 through early-October 2025, Skye Bioscience and its executives appear to have issued multiple public statements and earnings releases describing nimacimab as a "next-generation weight loss therapeutic" and highlighting preclinical and early-stage data. These communications included optimistic claims about nimacimab's profile and projected timelines for reporting clinical trial results. The investigation is examining whether these statements sufficiently reflected known risks regarding the drug's efficacy in humans, potential dosing inadequacies, and the possibility of failing to meet primary endpoints, and whether appropriate disclosures were included in the Company's public filings.

On October 6, 2025, Skye Bioscience announced topline results from its Phase 2a obesity trial, revealing that the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss and that pharmacokinetic exposure was lower than expected.

Following this news, Skye Bioscience's stock fell $2.85 per share, or approximately 60%, declining from $4.75 on October 3, 2025 to close at $1.90 on October 6, 2025.

If you purchased Skye Bioscience (NASDAQ: SKYE) between August 2024 and October 3, 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.